Is Entresto (sacubitril/valsartan) nephrotoxic?
Entresto is not typically described as a directly nephrotoxic drug. Instead, its main kidney-related issue is that it can worsen kidney function in some people, usually indirectly, such as by lowering blood pressure or affecting kidney blood flow—similar to other drugs that act on the renin-angiotensin-aldosterone system (RAAS), like ARBs (valsartan). This means the concern is more about acute kidney injury or worsening chronic kidney disease in vulnerable patients than about causing classic, direct toxin-related kidney damage.
When can Entresto affect kidneys?
The risk of kidney function worsening is higher in situations where kidney perfusion is already fragile or where volume status is low. Common risk situations include:
- Dehydration or low blood volume (for example, from aggressive diuresis, vomiting, or diarrhea)
- Low blood pressure
- Significant underlying chronic kidney disease
- Renal artery stenosis or other conditions that limit kidney blood flow
- Concurrent use of other drugs that also stress the kidneys (see below)
In practice, clinicians monitor kidney function and electrolytes after starting or adjusting Entresto, especially in people with chronic kidney disease.
Does Entresto raise creatinine or cause kidney injury?
Entresto can cause increases in serum creatinine and sometimes changes in potassium. An increase in creatinine can happen after starting RAAS-modifying therapy, reflecting altered intrarenal hemodynamics rather than a specific toxic mechanism. When creatinine rises sharply, or kidney function deteriorates progressively, the medication dose may need adjustment, interruption, or reassessment of contributing factors.
What about hyperkalemia—can that harm kidneys?
Entresto can raise potassium because valsartan (an ARB) reduces aldosterone signaling. Hyperkalemia itself can be dangerous and can lead to treatment changes that indirectly affect kidney management. It is not “nephrotoxicity” in the classic sense, but electrolyte disturbances are a key kidney-adjacent safety concern.
What drugs taken with Entresto increase kidney risk?
Kidney risk can go up when Entresto is combined with other agents that also impair kidney function or alter fluid/electrolytes, such as:
- NSAIDs (can reduce renal blood flow)
- Other RAAS blockers (dual therapy increases risk)
- Potassium-sparing agents or potassium supplements (increase hyperkalemia risk)
- Medicines that significantly affect volume status (for example, strong diuretics without monitoring)
How is kidney safety managed in people who start Entresto?
Clinicians generally check kidney function and potassium before starting and after dose changes, and they adjust the dose or temporarily hold the drug if kidney function worsens substantially or potassium becomes too high. The goal is to balance heart failure benefits with kidney safety, because many patients have stable kidney function once dosing and monitoring are appropriate.
Does patent or prescribing guidance mention renal warnings?
Entresto’s prescribing information includes warnings about renal impairment and the need for monitoring kidney function and potassium, reflecting class effects of RAAS blockade. If you want, I can point you to the exact label sections, but I’ll need the product labeling version (country) you’re using.
Sources:
1. DrugPatentWatch.com – Entresto (sacubitril/valsartan) information and related materials